Document:

Converted by EDGARwiz

Exhibit 4.30

AMENDMENT AGREEMENT  

December 23, 2010

This Amendment Agreement
(this “Agreement”) is entered into by and between IASO Pharma Inc., a Delaware corporation (the
“Company”), and Timothy Hofer (“Holder”) and amends the warrant to purchase shares of the
Company’s common stock, dated as of May 16, 2010, as amended as of September 16, 2010, issued by the Company to Holder (the
“Warrant”).  

RECITALS

WHEREAS
, pursuant to the terms of the Warrant, the Exercise Period (as
defined in the Warrant) is scheduled to commence on December 31, 2010 if a Qualified Financing (as defined in the Warrant) does
not occur by such date; and 

WHEREAS
, the 
Holder and the Company desire to amend the Warrant to extend the deadline for completing a Qualified
Financing and delay the commencement of the Exercise Period until March 31, 2011 on the terms set forth herein; 

NOW, THEREFORE, the parties agree as follows:

1.    Amendment.
 The first paragraph of the Warrant is hereby amended to replace references to “December 31, 2010” in the first and
third sentences thereof with “March 31, 2011.” 

2.

Miscellaneous

(a)

This Agreement may be
executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall
become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both
parties need not sign the same counterpart.  In the event that any signature is delivered by facsimile transmission, such
signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with
the same force and effect as if such facsimile signature page were an original thereof. 

(b)

This Agreement shall be
governed by the law of the State of New York without giving effect to any principles or conflicts of law. 

(d)

Except as expressly amended
hereby, the terms of the Warrant shall remain in full force and effect.

(e)

Each party shall do and
perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other
agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent
and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

(f)

Existing references to the
Warrant are henceforth deemed references to the Warrant as amended by this Agreement.

(g)

If any provision or portion
of this Agreement shall be determined to be invalid or unenforceable for any reason, in whole or in part, the remaining provisions
of this Agreement shall be unaffected thereby and shall remain in full force and effect to the fullest extent permitted by
law.

(h)

The headings contained in
this Agreement are for reference purposes only and shall not be deemed to be part of the Agreement or to affect the meaning or
interpretation of this Agreement.

(i)

All of the terms and
provisions of this Agreement shall bind and inure to the benefit of the parties hereto and their respective successors and
assigns.

(j)

This Agreement is intended
for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor
may any provision hereof be enforced by, any other person or entity.

  

[Remainder of page intentionally left blank]

2

IN WITNESS WHEREOF, the
parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first
indicated above. 

				
	
         
	
        IASO PHARMA INC.

	
          
	
          

	
          
	
          

	
          
	
        By: 
	
         /s/ Matthew A. Wikler, M.D.

	
          
	
        Name: 
	
         Matthew A. Wikler, M.D.

	
          
	
        Title: 
	
         President and CEO

	
         
	
         
	
         
	
         

			
	
         
	
        HOLDER

	
         
	
         

	
         
	
         
	
        /s/ Timothy M. Hofer

	
         
	
         
	
        Timothy M. HoferExhibit 4.31

 

AMENDMENT AGREEMENT

 

December 23, 2010

This Amendment Agreement (this “Agreement”) is entered into by and among IASO
Pharma Inc. (f/k/a Pacific Beach Biosciences, Inc.), a Delaware corporation (the “Company”), and Paramount Credit Partners, LLC (“Holder”). 

RECITALS

WHEREAS, Holder is the holder of a 10% Senior Promissory Note dated January 15, 2009 in the principal amount of
$2,750,000 and a 10% Senior Promissory Note dated June 24, 2009 in the principal amount of $125,000, each made by the Company in favor of Holder (collectively, the “Notes”),
which become due and payable upon a Qualified Financing (as defined in the Notes); 

WHEREAS, the Company is currently in the process of registering a proposed initial public offering of the
Company’s securities, which the Company anticipates will qualify as a Qualified Financing (the “IPO”); 

WHEREAS, the Company had previously engaged Maxim Group LLC (“Maxim”) as
the lead underwriter in connection with the IPO; however, Maxim recently represented to the Company that Maxim will not be able to raise the funds the Company requires in the IPO and, therefore, the Company has recently engaged Ladenburg
Thalmann & Co. Inc. (“Ladenburg”) to replace Maxim as the Company’s lead underwriter in connection with the IPO;

WHEREAS, Ladenburg Thalmann & Co. Inc. (“Ladenburg”), as
the lead underwriter for the IPO, has stressed to the Company that the requirement to repay the Notes in connection with the IPO would significantly inhibit the ability of the Company to successfully complete the IPO and, therefore, Ladenburg has
recommended that the Company obtain the Holder’s consent to amend the Notes;  

WHEREAS, as a result of such recommendation, the Company seeks the consent of the Holder to amend
the Notes to revise the definition of Qualified Financing exclude the IPO, on the terms set forth herein, in order to maximize the Company’s ability to complete the IPO; and

WHEREAS, the Holders agrees to amend the Notes on the terms set forth herein; and

AMENDMENT

	
            NOW, THEREFORE, the parties agree as follows:
 

1.            Amendment to the Notes.   The third
sentence of the second paragraph in Section 1 of the each of the Notes is hereby deleted and replaced in its entirety by the following (for ease of reference, changes are indicated by a single line through deleted text and underlining of inserted text):

All unpaid principal on this Note shall be due and payable on the earlier of (i) December 31, 2013; (ii) consummation by the Company of an equity financing
(or series of related equity financings), including without limitation a firm commitment subsequent to the Company’s underwritten initial public offering
pursuant to an effective registration statement under the Securities Act of 1933, as amended, involving the sale of equity securities in which the Company receives at least $10,000,000 in aggregate gross cash proceeds (before brokers’
fees or other transaction related expenses) (a “Qualified Financing”); and (iii) consummation of a merger, share exchange or other transaction (or 

 

 

series of related transactions), other than in connection with a Qualified Financing, in which (A) the Company merges into or otherwise becomes a wholly
owned subsidiary of a company subject to the public company reporting requirements of the Securities Exchange Act of 1934, as amended, and (B) the aggregate consideration payable to the Company or its stockholders in such transaction(s) is greater
than or equal to $10,000,000 (such period of time from the date of issuance hereof, the “Term”).

2.            Consent.  The Holder
hereby consents to the amendment to the Notes as set forth in Section 1 hereof. 

3.            Representations and Warranties of the Holder.  The Holder hereby represents and warrants to the Company that: 

 (a)         the Holder is the lawful holder of the Notes free and clear of all security
interests, claims, liens, pledges, conditional sales contracts, attachments, judgments and encumbrances of every kind and nature, including restrictions, or rights of any third parties;

 

 (b)        the Holder has the requisite power and authority to execute and deliver this
Agreement, to perform the Holder’s obligations hereunder and to engage in the transactions contemplated hereby;

 

 (c)         the Holder has taken all requisite action to make all the provisions of
this Agreement the valid and enforceable obligations they purport to be; and

 

 (d)        this Agreement constitutes the valid and binding obligation of the Holder,
enforceable in accordance with its terms, subject to laws of general application from time to time in effect affecting creditors' rights and the exercise of judicial discretion in accordance with general equitable principles.

 

4.             Representations and Warranties of the Company.  The Company hereby represents and warrants to the Holder that: 

 (a)         it has the requisite power and authority to execute and deliver this
Agreement, to perform its obligations hereunder and to engage in the transactions contemplated hereby;

 

 (b)        it has taken all requisite action to make all the provisions of this
Agreement the valid and enforceable obligations they purport to be; and

 

 (c)         this Agreement constitutes its valid and binding obligation,
enforceable in accordance with its terms, subject to laws of general application from time to time in effect affecting creditors' rights and the exercise of judicial discretion in accordance with general equitable principles.

 

	
             
 	
            5.
 	
            Miscellaneous
 

(a)          This Agreement may be executed in two or more counterparts, all of which
when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that the parties need not sign the
same counterpart.  In the event that any signature is delivered by facsimile transmission, such signature shall create a valid and binding obligation of the party executing (or on 

 

 

whose behalf such signature is executed) with the same force and effect as if such facsimile signature page were an original thereof. 

 (b)         This Agreement shall be governed by the law of the State of New York without
giving effect to any principles or conflicts of law. 

 (c)          Except as expressly amended hereby, the terms of the Notes shall remain
in full force and effect.

 (d)         Each party shall do and perform, or cause to be done and performed, all such
further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this
Agreement and the consummation of the transactions contemplated hereby.

 (e)         Existing references to the Notes are henceforth deemed references to the Notes
as amended by this Agreement.

(f)        If any provision or portion of this Agreement shall be determined to be invalid or
unenforceable for any reason, in whole or in part, the remaining provisions of this Agreement shall be unaffected thereby and shall remain in full force and effect to the fullest extent permitted by law.

(g)       The headings contained in this Agreement are for reference purposes only and shall not be
deemed to be part of this Agreement or to affect the meaning or interpretation of this Agreement.

(h)       All of the terms and provisions of this Agreement shall bind and inure to the benefit of
the parties hereto and their respective successors and assigns.

(i)        This Agreement is intended for the benefit of the parties hereto and their
respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person or entity.

 

[Remainder of page intentionally left blank]

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above. 

	
             
 	
            IASO PHARMA INC.
 
	
              
 	
              
 
	
              
 	
              
 
	
              
 	
            By: 
 	
            /s/ Matthew A. Wikler
 
	
              
 	
            Name: 
 	
            Matthew A. Wikler, M.D.
 
	
              
 	
            Title: 
 	
            President and CEO
 
	
             
 	
             
 	
             
 	
             
 

 

	
             
 	
            PARAMOUNT CREDIT PARTNERS, LLC
 
	
              
 	
              
 
	
              
 	
              
 
	
              
 	
            By: 
 	
            /s/ Lindsay A. Rosenwald
 
	
              
 	
            Name: 
 	
            Lindsay A. Rosenwald, M.D.
 
	
              
 	
            Title: 
 	
            Managing Member
 
	
             
 	
             
 	
             
 	
             
 

 

 

PCP Notes Amendment Agreement Signature Page

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}]]